Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INTERVIEW: Oraya doesn't see threat from new AMD drugs

This article was originally published in Clinica

Executive Summary

Oraya Therapeutics is ramping up commercialization of its radiotherapy for age-related macular degeneration (AMD), a treatment that could disrupt a market currently dominated by drug giants Novartis and Roche with their anti-VEGF drug Lucentis. Even with the advent of new AMD drugs, such as Regeneron’s approved anti-VEGF therapy Eylea (aflibercept injection) and Ophthotech’s investigational platelet-derived growth factor (PGDF) inhibitor Fovista, Oraya remains unperturbed by its pharma rivals.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101842

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel